Profund Advisors LLC lifted its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 102,352 shares of the biopharmaceutical company’s stock after buying an additional 447 shares during the period. Profund Advisors LLC’s holdings in Bristol-Myers Squibb were worth $5,703,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Connecticut Wealth Management LLC purchased a new position in Bristol-Myers Squibb in the 1st quarter worth approximately $224,000. Birmingham Capital Management Co. Inc. AL increased its stake in Bristol-Myers Squibb by 4.4% in the 1st quarter. Birmingham Capital Management Co. Inc. AL now owns 70,973 shares of the biopharmaceutical company’s stock worth $3,860,000 after purchasing an additional 3,000 shares during the period. HGK Asset Management Inc. increased its stake in Bristol-Myers Squibb by 20.8% in the 1st quarter. HGK Asset Management Inc. now owns 308,825 shares of the biopharmaceutical company’s stock worth $16,794,000 after purchasing an additional 53,221 shares during the period. Investment Partners Ltd. OH ADV increased its stake in Bristol-Myers Squibb by 1.4% in the 1st quarter. Investment Partners Ltd. OH ADV now owns 20,350 shares of the biopharmaceutical company’s stock worth $1,107,000 after purchasing an additional 274 shares during the period. Finally, Goelzer Investment Management Inc. increased its stake in Bristol-Myers Squibb by 85.4% in the 1st quarter. Goelzer Investment Management Inc. now owns 75,402 shares of the biopharmaceutical company’s stock worth $4,100,000 after purchasing an additional 34,735 shares during the period. 69.82% of the stock is currently owned by institutional investors.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $60.97 on Thursday. The firm has a market capitalization of $101,508.14, a P/E ratio of 20.95, a PEG ratio of 2.35 and a beta of 1.18. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. Bristol-Myers Squibb’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.77 earnings per share. equities research analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.
In related news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.23% of the company’s stock.
BMY has been the topic of a number of analyst reports. Goldman Sachs Group reaffirmed a “buy” rating and issued a $65.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price target on the stock. in a research note on Wednesday, August 9th. Jefferies Group reaffirmed a “buy” rating and issued a $66.00 price target (up from $63.00) on shares of Bristol-Myers Squibb in a research note on Thursday, August 24th. UBS reaffirmed a “buy” rating and issued a $72.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Finally, Citigroup lifted their price target on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $64.93.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.